Beyond Statins? BioAge Begins Pivotal Trial for Inflammation-Driven Heart Risk

EMERYVILLE, Calif. – June 16, 2026

BioAge Labs, a company built on decoding the science of human longevity, today announced a significant step in its mission to combat age-related disease. The first participant has been dosed in QUELL-CV, a pivotal Phase 2 clinical trial for its novel oral drug, BGE-102. The study aims to prove that targeting a core driver of chronic inflammation can substantially reduce cardiovascular risk, potentially heralding a new era in heart health management.

For decades, the fight against heart disease has been dominated by cholesterol-lowering statins. Yet, many patients on optimal therapy still suffer heart attacks and strokes, a reality that has pushed researchers to look for other culprits. A growing body of evidence points to chronic, low-grade inflammation as a major, modifiable risk factor on par with high LDL cholesterol.

BioAge's BGE-102 is designed to directly address this inflammatory component. The drug is a potent inhibitor of NLRP3, a protein complex that acts as a central alarm system for inflammation in the body. By quieting this alarm, BioAge hopes to quell the chronic inflammation that fuels atherosclerotic plaque development.

“Inflammation is increasingly recognized as a major modifiable driver of cardiovascular events, on par with elevated LDL cholesterol — and an oral therapy that addresses it could transform care and outcomes the way statins did decades ago,” said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. The initiation of this trial marks a critical test of that bold vision.

A New Front in the War on Heart Disease

The scientific rationale for targeting inflammation in heart disease is robust. The landmark CANTOS trial, which used an injectable antibody to target an inflammatory pathway, demonstrated for the first time that reducing inflammation could lower the rate of cardiovascular events. However, that therapy also came with an increased risk of serious infections, limiting its widespread use and creating a clear need for a safer, more targeted approach.

This is where NLRP3 inhibitors like BGE-102 enter the picture. NLRP3 is a key component of the “inflammasome,” a molecular machine that, when overactive, triggers the release of powerful inflammatory signals. This process, implicated in what scientists call “inflammaging,” is believed to be a fundamental driver of many chronic diseases of aging, from heart disease to neurodegeneration.

Doctors measure this systemic inflammation using a simple blood test for high-sensitivity C-reactive protein (hsCRP). Levels above 3 mg/L are associated with a high risk for future cardiovascular events. The primary goal of the QUELL-CV trial is to demonstrate a significant reduction in hsCRP, a biomarker that serves as a direct proxy for the drug's anti-inflammatory effect. The previously reported Phase 1 data for BGE-102 was striking, showing a median hsCRP reduction of 86% and normalizing levels in nearly all treated participants, positioning the drug as a potential best-in-class contender.

BioAge's Bet on Longevity Science

BioAge Labs is not a typical biopharmaceutical company. Its strategy is rooted in geroscience—the idea that by targeting the fundamental mechanisms of aging itself, one can prevent or treat multiple age-related diseases simultaneously. The company’s unique discovery platform analyzes biological data from cohorts of exceptionally long-lived, healthy individuals to identify pathways that confer resilience to disease.

It was this platform that pointed to the NLRP3 pathway as a key therapeutic target. The data suggested that naturally lower NLRP3 activity is associated with greater longevity, providing a powerful, human-genetics-based validation for their approach. This strategy has resonated with investors and analysts. Since its IPO in late 2024, BioAge has secured a strong financial position, with a cash runway projected by analysts at Roth/MKM to last into 2029, giving it the stability to pursue its ambitious clinical programs.

The QUELL-CV trial is designed to provide the rigorous data needed to move forward. It is a randomized, double-blind, placebo-controlled study that will enroll approximately 160 adults with obesity, elevated hsCRP, and at least one other cardiovascular risk factor. Participants will receive one of three once-daily oral doses of BGE-102 or a placebo for 12 weeks.

“QUELL-CV is designed to characterize the dose-response relationship of BGE-102's effect on hsCRP across three oral once-daily dose levels,” said Paul Rubin, M.D., Chief Medical Officer of BioAge. The study will also assess the drug's impact on a broad range of other inflammatory and metabolic biomarkers, providing a comprehensive picture of its biological activity.

The Promise and Profile of BGE-102

What makes BGE-102 particularly compelling is its profile. As a once-daily oral pill, it offers a level of convenience and accessibility that injectable biologics cannot match—a critical feature for a preventative therapy intended for millions. Furthermore, BGE-102 is brain-penetrant, meaning it can cross the blood-brain barrier. This property opens the door to treating a host of other inflammation-driven conditions, including neurodegenerative and retinal diseases.

The NLRP3 inhibitor space is becoming increasingly competitive, with companies like Ventyx Biosciences and larger players like Roche and Bristol-Myers Squibb actively developing candidates for various inflammatory disorders. However, BioAge has established a strong position with BGE-102, particularly with its dual focus on the massive cardiovascular market and specialized indications.

Its impressive Phase 1 data not only showed profound hsCRP reductions but also demonstrated an excellent safety profile. The drug was well-tolerated at all doses, with no serious adverse events, suggesting it may avoid the safety concerns that have hampered other anti-inflammatory approaches. According to one leading drug development expert, a potent, safe, oral NLRP3 inhibitor could become a foundational therapy for a wide range of chronic conditions.

Broader Horizons: From Heart to Eye and Beyond

BioAge is already looking beyond cardiovascular disease. The company plans to initiate another proof-of-concept trial in mid-2026 to evaluate BGE-102 as a treatment for diabetic macular edema (DME), a leading cause of blindness in diabetic patients where inflammation plays a crucial role. This move highlights the “platform-in-a-pill” potential of BGE-102, leveraging its mechanism to address multiple unmet needs stemming from the same underlying biology of aging.

This strategy embodies the core promise of geroscience: a single intervention targeting a fundamental aging pathway could yield benefits across multiple organ systems, improving not just lifespan but healthspan—the years lived free from disease and disability.

All eyes in the field will now be on the QUELL-CV trial. With topline data anticipated in the second half of 2026, the results will provide a crucial verdict on the potential of BGE-102 to become a transformative therapy. More than that, it will be a telling test of BioAge's pioneering strategy of turning the secrets of human longevity into the medicines of tomorrow.